ClinicalTrials.gg
CompletedNCT01300013Updated Jul 27, 2021

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

A Phase 2 interventional study of Placebo and Omecamtiv mecarbil in Heart Failure, sponsored by Cytokinetics. Completed at 150 sites in 19 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Cytokinetics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
614
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing omecamtiv mecarbil in Heart Failure — 1 open to participants now, 1 under way, 1 of them phase 3. omecamtiv mecarbil · Heart Failure.

Enrollment
3rd of 14
614 · median 48
Started
2011
the only one that year
Phase 2
7 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
14 of 14
Cytokinetics

Among the 14 studies testing omecamtiv mecarbil in Heart Failure, this one is the 3rd largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 6th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,394 are open to participants now.

Browse Heart Failure studies →

Open to participants now

1 of the 14 studies testing omecamtiv mecarbil in Heart Failure is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About omecamtiv mecarbil

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 967 Heart Failure studies recruiting now, 690 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing omecamtiv mecarbil in Heart Failure, or all of them as a file.
02

Study summary

The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure. This is a multicenter, randomized, double-blind, placebo-controlled study with 3 dose cohorts enrolled sequentially in order of ascending dose strength of omecamtiv mecarbil. In each cohort, subjects are randomized 1:1 to omecamtiv mecarbil or placebo.

Read the detailed description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

03

Conditions studied

  • Heart Failure

Keywords

  • Intravenous
  • IV
  • Left Ventricular Systolic Dysfunction
  • Hospitalized
  • Acute heart failure
  • Heart failure
  • Left ventricular ejection fraction
  • pharmacokinetics
  • Pharmacodynamics
  • Dyspnea
  • hospitalization
  • In-patient
  • Omecamtiv mecarbil
  • Double-blind
  • Randomized
  • Placebo-controlled
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female 18 - 85 years
  • Hospitalized for worsening heart failure, within 24 hours of initiating IV loop diuretic
  • Dyspnea due to heart failure, at rest or with minimal exertion
  • History of (LVEF) ≤ 40%
  • Elevated brain natriuretic peptide (BNP) or N-terminal fragment BNP (NT-proBNP)

Exclusion criteria

Exclusion Criteria:

  • Receiving IV vasopressor (excluding low dopamine), inotropic or mechanical support
  • Acute coronary syndrome (ACS)
  • Within 30 days prior to enrollment: cardiac resynchronization therapy (CRT) or implantable cardioverter defibrillator (ICD) implantation, ACS, coronary revascularization, (TIA) or stroke, sustained ventricular arrhythmia, or major surgery
  • Severe valvular stenosis, hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or congenital heart disease
  • Estimated (eGFR) \< 20 mL/min/1.73m2
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
614 participants (actual)

Study arms

  • Experimental
    Omecamtiv mecarbil

    Drug: Omecamtiv mecarbil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugPlacebo

    48-hour infusion of placebo

  • 48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.

    Also known as: CK-1827452, AMG 423

06

What researchers measure

Primary outcomes

  1. The primary objective of the study is to evaluate the effect of 48 hours of intravenous (IV) omecamtiv mecarbil compared with placebo on dyspnea in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure.

    Time frame: 48 hours

Secondary outcomes

  1. To characterize pharmacokinetics of omecamtiv mecarbil including metabolites following IV infusion and to evaluate the relationship between omecamtiv mecarbil plasma concentration and echocardiographic parameters in subjects with AHF

    Time frame: 48 hours

  2. To assess the safety and tolerability of 3 dose levels of IV omecamtiv mecarbil compared with placebo in subjects with left ventricular systolic dysfunction hospitalized for acute heart failure

    Time frame: 48 hours

  3. To evaluate the effects of 48 hours treatment with IV omecamtiv mecarbil on additional measures of dyspnea, patient global assessment (PGA), change in NT-proBNP, incidence of worsening heart failure, and short term clinical outcomes

    Time frame: 48 hours

07

Study locations

150 sites
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Inglewood, California 90301, United States
  • Research Site
    La Jolla, California 92037, United States
  • Research Site
    San Francisco, California 94121, United States
  • Research Site
    Danbury, Connecticut 06810, United States
  • Research Site
    Newark, Delaware 19718, United States
  • Research Site
    Atlantis, Florida 33462, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Fort Lauderdale, Florida 33308, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Orlando, Florida 32803, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60611, United States
  • Research Site
    Peoria, Illinois 61636, United States
  • Research Site
    Baltimore, Maryland 21201, United States
  • Research Site
    Detroit, Michigan 48201, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Novi, Michigan 48374, United States
  • Research Site
    Minneapolis, Minnesota 55417, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Lincoln, Nebraska 68506, United States
  • Research Site
    Newark, New Jersey 07103, United States
  • Research Site
    Bronx, New York 10467, United States
  • Research Site
    Cortlandt Manor, New York 10567, United States
  • Research Site
    Roslyn, New York 11576, United States
  • Research Site
    Chapel Hill, North Carolina 27599, United States
  • Research Site
    Charlotte, North Carolina 28204, United States
  • Research Site
    Durham, North Carolina 27705, United States
  • Research Site
    Winston-Salem, North Carolina 27103, United States
  • Research Site
    Cincinnati, Ohio 45219, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Cleveland, Ohio 44109, United States
  • Research Site
    Columbus, Ohio 43210, United States
  • Research Site
    Fairfield, Ohio 45014, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    Charleston, South Carolina 29425, United States
  • Research Site
    Greenville, South Carolina 29605, United States
  • Research Site
    Memphis, Tennessee 38120, United States
  • Research Site
    Nashville, Tennessee 37203, United States
  • Research Site
    Nashville, Tennessee 37232-8802, United States
  • Research Site
    Tullahoma, Tennessee 37388, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Murray, Utah 84107, United States
  • Research Site
    Darlinghurst, New South Wales 2010, Australia
  • Research Site
    Woolloongabba, Queensland 4102, Australia
  • Research Site
    Bedford Park, South Australia 5042, Australia
  • Research Site
    Prahran, Victoria 3181, Australia
  • Research Site
    Richmond, Victoria 3121, Australia
  • Research Site
    Aalst, 9300, Belgium
  • Research Site
    Bonheiden, 2820, Belgium
  • Research Site
    Gent, 9000, Belgium
  • Research Site
    Roeselare, 8800, Belgium
  • Research Site
    Blagoevgrad, 2700, Bulgaria
  • Research Site
    Kazanlak, 6100, Bulgaria
  • Research Site
    Pazardzhik, 4700, Bulgaria
  • Research Site
    Plovdiv, 4002, Bulgaria
  • Research Site
    Sandanski, 2800, Bulgaria
  • Research Site
    Smolyan, 4400, Bulgaria
  • Research Site
    Sofia, 1309, Bulgaria
  • Research Site
    Sofia, 1431, Bulgaria
  • Research Site
    Sofia, 1527, Bulgaria
  • Research Site
    Calgary, Alberta T2N 4Z6, Canada
  • Research Site
    Edmonton, Alberta T6G 2B7, Canada
  • Research Site
    Edmonton, Alberta T6L 5X8, Canada
  • Research Site
    Halifax, Nova Scotia B3H 3A7, Canada
  • Research Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Research Site
    Toronto, Ontario M5B 1W8, Canada
  • Research Site
    Toronto, Ontario M5G 1X5, Canada
  • Research Site
    Montreal, Quebec H3G 1A4, Canada
  • Research Site
    Québec, Quebec G1V 4G5, Canada
  • Research Site
    Sherbrooke, Quebec J1H 5N4, Canada
  • Research Site
    Brno, 625 00, Czechia
  • Research Site
    Brno, 656 91, Czechia
  • Research Site
    Praha 2, 128 08, Czechia
  • Research Site
    Praha 5, 150 06, Czechia
  • Research Site
    Usti nad Labem, 401 13, Czechia
  • Research Site
    Helsinki, 00029, Finland
  • Research Site
    Turku, 20521, Finland
  • Research Site
    Caen Cedex 9, 14033, France
  • Research Site
    Lille Cedex, 59037, France
  • Research Site
    Montpellier cedex 05, 34295, France
  • Research Site
    Paris Cedex 13, 75651, France
  • Research Site
    Paris, 75010, France
  • Research Site
    Strasbourg, 67091, France
  • Research Site
    Toulouse Cedex 09, 31403, France
  • Research Site
    Bad Nauheim, 61231, Germany
  • Research Site
    Dortmund, 44137, Germany
  • Research Site
    Dresden, 01307, Germany
  • Research Site
    Frankfurt, 60488, Germany
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    Greifswald, 17475, Germany
  • Research Site
    Halle/Saale, 06097, Germany
  • Research Site
    Hamburg, 20246, Germany
  • Research Site
    Homburg, 66421, Germany
  • Research Site
    Langen, 63225, Germany
  • Research Site
    Regensburg, 93053, Germany
  • Research Site
    Stuttgart, 70376, Germany
  • Research Site
    Würzburg, 97080, Germany

Showing the first 100 of 150 sites across 19 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Teerlink JR, Felker GM, McMurray JJV, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JGF, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM; ATOMIC-AHF Investigators. Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. J Am Coll Cardiol. 2016 Mar 29;67(12):1444-1455. doi: 10.1016/j.jacc.2016.01.031. PubMed 27012405 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Apr 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2011
First posted
Feb 21, 2011
Start
Apr 2011
Primary completionActual
Apr 2013
CompletionActual
Sep 2013
Results delay requested
Jan 15, 2014
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01300013
Lead sponsor
Cytokinetics
Responsible party
Sponsor
First posted
Feb 21, 2011
Start date
Apr 2011
Primary completion
Apr 2013
Completion
Sep 2013
Last update
Jul 27, 2021

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Omecamtiv mecarbil

Start the discussion